Orthopediatrics Corp (KIDS) Stock Price & Analysis

Orthopediatrics Corp (KIDS) rose 0.80% to USD 18.87 as of July 25, 2026 at 05:13 UTC, according to Nexqual real-time market data.

KIDS last closed at USD 18.72; the session ranged USD 18.1–19.22 on volume of 133,167 shares. Market capitalization is $484.68M, with a 52-week range of USD 14.42–23.07 (NGM). Source: Nexqual, July 25, 2026 at 05:13 UTC.

Key Statistics (as of July 25, 2026 at 05:13 UTC)

Technical Analysis (KIDS)

Nexqual's technical model rates KIDS "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 05:13 UTC.

Analyst Ratings (KIDS)

Wall Street analysts rate KIDS "Buy" based on 9 analysts, with a mean price target of USD 25 (range USD 20–34), per Nexqual as of July 25, 2026 at 05:13 UTC.

Earnings (KIDS)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 05:13 UTC.

Financials & Fundamentals (KIDS)

Source: Nexqual, July 25, 2026 at 05:13 UTC.

Financial Health Score (KIDS)

Nexqual rates Orthopediatrics Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:13 UTC.

Ownership (KIDS)

Source: Nexqual, July 25, 2026 at 05:13 UTC.

Leadership (KIDS)

Orthopediatrics Corp is led by David R. Bailey (age 46), President, CEO & Director, per Nexqual as of July 25, 2026 at 05:13 UTC.

Major Backers & Investors (KIDS)

Notable institutional backers of Orthopediatrics Corp include Brown Advisory Inc., Millennium Management, Morgan Stanley, according to Nexqual as of July 25, 2026 at 05:13 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 05:13 UTC.

From Orthopediatrics Corp's Latest SEC 10-K Filing (filed 2026-03-04)

Key Strengths & Strategy (as disclosed to the SEC)

• In 2022, we acquired MD Ortho, a manufacturer of orthopedic clubfoot products, and Pega Medical, a medical device company which sells a portfolio of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System designed to treat osteogenesis imperfecta.
• We estimate that the portion of this market that we currently serve represents a $6.2 billion opportunity globally, including over $2.8 billion in the United States.
• Market Opportunity We currently serve a portion of the pediatric orthopedic implant market that we estimate represents a $6.2 billion opportunity globally, including over $2.8 billion in the United States.
• Our global revenue from this category for the year ended December 31, 2025 was $166.3 million, an increase of 15% over the prior year, and represented 70% of total revenue.

Partnerships

• Beyond working with them to develop innovative products, we intend to deepen our partnership with surgeons by leveraging the experience of our senior management team, including our Medical Director, to expand our clinical education programs and partnerships with teaching hospitals, sponsor surgical workshops for residents and fellows and support worthwhile clinical research projects.
• Our broad product offering has made us, within the three categories of the market that we currently serve, the only provider of comprehensive solutions to pediatric orthopedic surgeons, who for the most part are generalists performing a wide range of orthopedic surgeries. 14 •    Partnership with Pediatric Orthopedic Surgeons and Pediatric Surgical Societies.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:13 UTC. This page is informational and not investment advice.